Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC in HER2-positive advanced urothelial carcinoma
CTR20180438Phase 2Completed
- Sponsor
- RemeGen
- Start
- Apr 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in transitional cell carcinoma (TCC), sponsored by RemeGen. Started Apr 2018; status: completed.
02
Drugs
disitamab vedotin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20180438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180438.